RT Journal Article
SR Electronic
T1 In vitro, classical complement activation differs by disease severity and between SARS-CoV-2 antigens
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.22.21266681
DO 10.1101/2021.11.22.21266681
A1 Lamerton, Rachel E
A1 Marcial-Juarez, Edith
A1 Faustini, Sian E
A1 Perez-Toledo, Marisol
A1 Goodall, Margaret
A1 Jossi, Siân E
A1 Newby, Maddy L
A1 Chapple, Iain
A1 Dietrich, Thomas
A1 Veenith, Tonny
A1 Shields, Adrian M
A1 Harper, Lorraine
A1 Henderson, Ian R
A1 Rayes, Julie
A1 Wraith, David C
A1 Watson, Steve P
A1 Crispin, Max
A1 Drayson, Mark T
A1 Richter, Alex G
A1 Cunningham, Adam F
YR 2021
UL http://medrxiv.org/content/early/2021/11/24/2021.11.22.21266681.abstract
AB Antibodies specific for the spike glycoprotein (S) and nucleocapsid (N) SARS-CoV-2 proteins are typically present during severe COVID-19, and induced to S after vaccination. The binding of viral antigens by antibody can initiate the classical complement pathway. Since complement could play pathological or protective roles at distinct times during SARS-CoV-2 infection we determined levels of antibody-dependent complement activation along the complement cascade. Here, we used an ELISA assay to assess complement protein binding (C1q) and the deposition of C4b, C3b, and C5b to S and N antigens in the presence of anti-SARS-CoV-2 antibodies from different test groups: non-infected, single and double vaccinees, non-hospitalised convalescent (NHC) COVID-19 patients and convalescent hospitalised (ITU-CONV) COVID-19 patients. C1q binding correlates strongly with antibody responses, especially IgG1 levels. However, detection of downstream complement components, C4b, C3b and C5b shows some variability associated with the antigen and subjects studied. In the ITU-CONV, detection of C3b-C5b to S was observed consistently, but this was not the case in the NHC group. This is in contrast to responses to N, where median levels of complement deposition did not differ between the NHC and ITU-CONV groups. Moreover, for S but not N, downstream complement components were only detected in sera with higher IgG1 levels. Therefore, the classical pathway is activated by antibodies to multiple SARS-CoV-2 antigens, but the downstream effects of this activation may differ depending on the specific antigen targeted and the disease status of the subject.Spike- and nucleocapsid-specific antibodies activate complement in vitroC1q binding correlates with IgG1 antibody levelsGeneration of C4b, C3b and C5b relates to the antigen targeted and the patient group testedCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Wellcome Trust Mechanisms of Inflammatory Disease (MIDAS) PhD Programme [grant number 222389/Z/21/Z, part of 108871/B/15/Z] to R.E.L; The Royal Society Newton International Fellowship [grant number NIF\R1\192061] to E.M.J and A.F.C; a British Heart Foundation Intermediate Fellowship [grant number FS/IBSRF/20/25039] to J.R; The University of Southampton Coronavirus Response Fund to M.C and Medical Research Council [grant number MR/W010011/1] to L.H, A.G.R and A.F.C.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:London Camden and Kings Cross Research Ethics Committee, reference 20/HRA/1817, gave ethical approval for this work. North West ethics committee, Preston CIA UPH IRAS approval reference REC 20\NW\0240, gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript